Tseghai Berhe, MD
Pediatric Endocrinology · Hoffman Estates, ILNPI 1982678207
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,662 of the $8,842 with a category attached, or 64.0%. 39 manufacturers reported payments, led by Novo Nordisk at 42.0% of the total. Reporting peaked in 2019 at $3,993 and has fallen 82.9% since, to $684 in 2025.
Across 270 payments — averaging $32.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$4K
- Ascendis Pharma Endocrinology Inc$879
- Mannkind Corporation$659
- AbbVie$431
- Tolmar Pharmaceuticals, Inc.$264
- Neurocrine Biosciences, Inc.$256
- plus $3K from 33 others
What the payments were for
- Speaking & faculty fees$2,66630%
- Travel & lodging$4345%
- Food & beverage$5,66264%
- Education$791%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 35 | $3,716 |
| Ascendis Pharma Endocrinology Inc | 34 | $879 |
| Mannkind Corporation | 39 | $659 |
| AbbVie | 20 | $431 |
| Tolmar Pharmaceuticals, Inc. | 14 | $264 |
| Neurocrine Biosciences, Inc. | 9 | $256 |
| Kyowa Kirin, Inc. | 10 | $245 |
| Medtronic(2 entities) | 5 | $238 |
| Xeris Pharmaceuticals, Inc. | 13 | $238 |
| Insulet Corporation | 9 | $238 |
| Sanofi-aventis U.S. LLC | 5 | $197 |
| Dexcom, Inc. | 10 | $161 |
| Sandoz | 6 | $147 |
| Pfizer | 9 | $125 |
| Zealand Pharma US, Inc. | 5 | $101 |
| AstraZeneca(2 entities) | 5 | $95 |
| Ultragenyx Pharmaceutical Inc. | 5 | $88 |
| Lifescan, Inc. | 5 | $85 |
| Amneal Pharmaceuticals LLC | 4 | $83 |
| Endo USA, Inc. | 3 | $74 |
| Tandem Diabetes Care, Inc. | 3 | $74 |
| Amgen(2 entities) | 2 | $52 |
| BETA Bionics, Inc. | 2 | $45 |
| Acella Pharmaceuticals, LLC | 2 | $41 |
| Embecta Corp. | 1 | $31 |
| Arbor Pharmaceuticals, Inc. | 2 | $27 |
| Ascensia Diabetes Care US Inc. | 1 | $26 |
| Corcept Therapeutics | 1 | $25 |
| Eton Pharmaceuticals, Inc. | 1 | $24 |
| Rhythm Pharmaceuticals, Inc. | 1 | $23 |
| Amryt Pharma Holdings Ltd | 1 | $22 |
| Lilly USA, LLC | 1 | $21 |
| Tolmar, Inc. | 1 | $21 |
| Abbott | 1 | $19 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Vistapharm, Inc. | 1 | $15 |
| Biomarin Pharmaceutical Inc. | 1 | $14 |
| Companion Medical, Inc. | 1 | $14 |
| IBSA Pharma Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Norditropin$3,101
- TZIELD$126
- SKYTROFA$125
- INTELLIS ADAPTIVESTIM$107
How this compares
$8,842 in reported general payments places this provider in the 75th percentile of 61 pediatric endocrinology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 61 | $62,901 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 36 | $46,758 |
| MounjaroTirzepatide | 39 | $42,484 |
| JanuviaSitagliptin Phosphate | 41 | $33,039 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 43 | $31,923 |
| FarxigaDapagliflozin Propanediol | 27 | $20,793 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 11 | $20,165 |
| InvokanaCanagliflozin | 22 | $12,379 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $7,458 |
| Novolog FlexpenInsulin Aspart | 18 | $6,443 |
| Alcohol Prep PadsAlcohol Antiseptic Pads | 87 | $6,409 |
| Ultra-Fine Nano Pen NeedlePen Needle, Diabetic | 14 | $3,472 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 20 | $2,333 |
| Levothyroxine Sodium | 69 | $1,461 |
| Ammonium Lactate | 25 | $893 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $3,716 | $62,90161 claims |
| Lilly USA, LLCMounjaro | $21 | $42,48439 claims |
| AstraZenecaFarxiga | $95 | $20,79327 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $83 | $1,46169 claims |
| AbbVieArmour Thyroid | $431 | $73817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 61 pediatric endocrinology providers in Illinois.
Other pediatric endocrinology in Hoffman Estates
- Kristen BishopHoffman Estates$8K
- Anita SwamyChicago$1.4M
- Stuart KupferDeerfield$196K
- Mary McCauleyWinfield$170K
- Kanika GhaiPark Ridge$139K
- Angela Ganan PopaElk Grove Village$62K
- Courtney FinlaysonChicago$46K
- Stelios MantisChicago$27K
- William ZellerWheaton$15K
- Magdalena DuminPark Ridge$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.